Abeona Therapeutics (NASDAQ:ABEO) on Wednesday reported financial results for the full year ended December 31, 2025, and provided operational updates centered on the commercial launch of its lead gene therapy ZEVASKYN.
X4 Pharmaceuticals (NASDAQ:XFOR) reported its fourth-quarter and full-year 2025 financial results on March 17, 2026, marking a year of transition from a clinical-stage entity to a commercial-revenue-generating firm.
Pfizer (NYSE:PFE) reported a significant clinical milestone in its oncology pipeline today, announcing that the Phase 2 FOURLIGHT-1 study of atirmociclib met its primary endpoint.
BioCardia (NASDAQ:BCDA) announced on Tuesday that the U.S. Food and Drug Administration has accepted its pre-submission package for the Helix Transendocardial Delivery Catheter.
AtaiBeckley (NASDAQ:ATAI) announced on Tuesday that results from a Phase 2a cohort evaluating BPL-003, its proprietary intranasal formulation of 5-MeO-DMT, have been published in the Journal of Psychopharmacology.
Greenwich LifeSciences (NASDAQ:GLSI) released a preliminary update from its ongoing Phase III FLAMINGO-01 clinical trial, which evaluates the efficacy of GP2, an immunotherapy designed to prevent breast cancer recurrences.
Zenas BioPharma (NASDAQ:ZBIO) announced its full-year 2025 financial results on March 16, 2026, marking a pivotal year that has positioned the Waltham, Massachusetts-based biotech for its first potential product launch.
Olema Oncology (NASDAQ:OLMA) announced its fourth-quarter and full-year 2025 financial results on Monday, highlighting a year of substantial capital formation and clinical acceleration.
Relay Therapeutics (NASDAQ:RLAY) announced clinical data from its Phase 1/2 ReDiscover trial on Monday, providing a significant update on the efficacy and safety of zovegalisib (formerly RLY-2608).
Canopy Growth (NASDAQ:CGC) and MTL Cannabis announced the successful closing of their previously disclosed arrangement on Monday.
Annovis Bio (NYSE:ANVS) reported its full-year 2025 financial results and clinical milestones on March 16, 2026, highlighting a period of aggressive execution for its neurodegenerative disease pipeline.
Nasus Pharma (NYSE:NSRX) announced positive topline results from its Phase 2 clinical study of NS002, a proprietary intranasal epinephrine powder designed to treat life-threatening allergic reactions.
